AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33235115 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 216
Study 36049646 — intervention group
Group type: EXPERIMENTAL
Intervention: RLRL therapy (100% power)
Number of subjects: 112
Study 36049646 — intervention group
Group type: COMPARATOR
Intervention: Sham device (10% power)
Number of subjects: 112
Study 34285318 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined NMES with MCE (COMB)
Number of subjects: 60
Study 34285318 — intervention group
Group type: COMPARATOR
Intervention: Sham-NMES with MCE (MCE)
Number of subjects: 60
Study 34285318 — intervention group
Group type: COMPARATOR
Intervention: NoLBP group
Number of subjects: 60
Study 32466496 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance fitness group based on Zumba Fitness classes (DF group, n = 25)
Number of subjects: 65
Study 32466496 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance fitness + functional strength training group (DFFT group, n = 20)
Number of subjects: 65
Study 32466496 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 65
Study 35281702 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week web-based self-help program
Number of subjects: 152
Study 35281702 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 152
Study 32420972 — intervention group
Group type: EXPERIMENTAL
Intervention: Lertal® nutraceutical (active group, AG)
Number of subjects: 0
Study 32420972 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 0
Study 35569503 — intervention group
Group type: EXPERIMENTAL
Intervention: EMPOWER
Number of subjects: 86
Study 35569503 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 86
Study 32023185 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n = 23)
Number of subjects: 46
Study 32023185 — intervention group
Group type: COMPARATOR
Intervention: Wait-list group (n = 23)
Number of subjects: 46
Study 35718656 — intervention group
Group type: EXPERIMENTAL
Intervention: tedizolid phosphate 200 mg once daily for 7 days
Number of subjects: 53
Study 35718656 — intervention group
Group type: COMPARATOR
Intervention: linezolid 600 mg twice daily for 10 days
Number of subjects: 53
Study 33812218 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine (900mg/day)
Number of subjects: 65
Study 33812218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 35034050 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized response technique (RRT)
Number of subjects: 0
Study 35034050 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic characteristics (younger, college education, single, employed, Han ethnicity, diagnosed with HIV in the past 6 years, not on antiretroviral therapy)
Number of subjects: 0
Study 33758387 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol treatment
Number of subjects: 638
Study 33758387 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 638
Study 33113596 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole (100 mg/d for 8 weeks)
Number of subjects: 74
Study 33113596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 35272400 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Neimadian and Zusanli (ST 36), 2 Hz/100 Hz frequency, 1 mA intensity, lasting 30 min.
Number of subjects: 80
Study 35272400 — intervention group
Group type: COMPARATOR
Intervention: Tramadol hydrochloride injection, 1 mg/kg intravenously.
Number of subjects: 80
Study 32518394 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.15% ophthalmic solution
Number of subjects: 36
Study 32518394 — intervention group
Group type: COMPARATOR
Intervention: Control (artificial tear instilled in left eye)
Number of subjects: 36
Study 33724358 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental factors (relative humidity, temperature, floor covering type, number of occupants)
Number of subjects: 64
Study 33724358 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust mites (D. pteronyssinus and D. farinae)
Number of subjects: 64
Study 33724358 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean density of house dust mites
Number of subjects: 64
Study 32147053 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt water bath (Group B) - 250 grams of powdered mineral salt dissolved in warm water (40-45 °C) for 15 minutes each night for one month.
Number of subjects: 60
Study 32147053 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm water bath (Group A) - warm tolerable water (40-45 °C) for 15 minutes each night for one month.
Number of subjects: 60
Study 32147053 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C) - no intervention.
Number of subjects: 60
Study 35585604 — intervention group
Group type: EXPERIMENTAL
Intervention: Legume-based DASH diet
Number of subjects: 300
Study 35585604 — intervention group
Group type: COMPARATOR
Intervention: DASH diet
Number of subjects: 300
Study 33234158 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (2 tablets of 6 mg for patients 48-80 kg, 3 tablets for 80-110 kg, 4 tablets for >110 kg) administered at inclusion and 24 hours later.
Number of subjects: 500
Study 33234158 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 tablets of 6 mg for patients 48-80 kg, 3 tablets for 80-110 kg, 4 tablets for >110 kg) administered at inclusion and 24 hours later.
Number of subjects: 500
Study 33234158 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 500
Study 33234158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 35589070 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition literacy level assessed using the Nutrition Literacy Assessment Instrument
Number of subjects: 112
Study 35589070 — intervention group
Group type: EXPERIMENTAL
Intervention: Low nutrition literacy
Number of subjects: 112
Study 32281579 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g AZD0585
Number of subjects: 383
Study 32281579 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g AZD0585
Number of subjects: 383
Study 32281579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 383
Study 32281579 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD0585
Number of subjects: 383
Study 35718790 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltodextrin and fructose beverage (800 mL at 10 hours and 400 mL at 2 hours before surgery)
Number of subjects: 231
Study 35718790 — intervention group
Group type: COMPARATOR
Intervention: Water (control group)
Number of subjects: 231
Study 33409924 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc therapy
Number of subjects: 105
Study 33409924 — intervention group
Group type: COMPARATOR
Intervention: No zinc therapy (Control)
Number of subjects: 105
Study 36374436 — intervention group
Group type: EXPERIMENTAL
Intervention: Remotely delivered EnhanceFitness (tele‐EF) exercise program, 1 hour, 3 days/week for 16 weeks (n=20)
Number of subjects: 39
Study 36374436 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (n=19)
Number of subjects: 39
Study 33243300 — intervention group
Group type: EXPERIMENTAL
Intervention: Unguided StudiCare Mindfulness (StudiCare-M)
Number of subjects: 387
Study 33243300 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidance on Demand (GoD) StudiCare Mindfulness (StudiCare-M)
Number of subjects: 387
Study 33243300 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 387
Study 36118673 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (5 mg daily) plus original oral hypoglycemic agents
Number of subjects: 80
Study 36118673 — intervention group
Group type: COMPARATOR
Intervention: Original oral hypoglycemic agents alone (control group)
Number of subjects: 80
Study 34225743 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital chest drain
Number of subjects: 209
Study 34225743 — intervention group
Group type: COMPARATOR
Intervention: Traditional chest drain
Number of subjects: 209
Study 32590183 — intervention group
Group type: EXPERIMENTAL
Intervention: Conclusions of arguments
Number of subjects: 0
Study 32590183 — intervention group
Group type: COMPARATOR
Intervention: Assertions
Number of subjects: 0
Study 33931815 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan (sac/val)
Number of subjects: 0
Study 33931815 — intervention group
Group type: COMPARATOR
Intervention: enalapril
Number of subjects: 0
Study 33845654 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmucosal diamorphine
Number of subjects: 28
Study 33845654 — intervention group
Group type: COMPARATOR
Intervention: Oral morphine
Number of subjects: 28
Study 32490924 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical headgear
Number of subjects: 45
Study 32490924 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated individuals)
Number of subjects: 45
Study 35845981 — intervention group
Group type: EXPERIMENTAL
Intervention: External radiation therapy
Number of subjects: 30
Study 33227589 — intervention group
Group type: EXPERIMENTAL
Intervention: Animated characters
Number of subjects: 92
Study 33227589 — intervention group
Group type: COMPARATOR
Intervention: Live-action humans
Number of subjects: 92
Study 33227589 — intervention group
Group type: EXPERIMENTAL
Intervention: Animals
Number of subjects: 92
Study 33227589 — intervention group
Group type: COMPARATOR
Intervention: Animated anthropomorphic animals
Number of subjects: 92
Study 35908254 — intervention group
Group type: EXPERIMENTAL
Intervention: Masupirdine treatment
Number of subjects: 564
Study 35908254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 564
Study 34981468 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (500 mg/day)
Number of subjects: 79
Study 34981468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 35073129 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief online educational intervention
Number of subjects: 1297
Study 35073129 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1297
Study 32964379 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-aortic axial flow devices (Impella)
Number of subjects: 0
Study 32964379 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal centrifugal pumps
Number of subjects: 0
Study 32964379 — intervention group
Group type: EXPERIMENTAL
Intervention: New TCS platforms
Number of subjects: 0
Study 32964379 — intervention group
Group type: EXPERIMENTAL
Intervention: Systems of care
Number of subjects: 0
Study 33597439 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal vitamin A supplementation (10,000 IU three times per week until delivery, followed by 200,000 IU at delivery and every three months until infants were 12 months old)
Number of subjects: 152
Study 33597439 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered at the same frequency as the vitamin A supplementation)
Number of subjects: 152
Study 35150610 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma (250-300 mL of high anti-SARS-CoV-2 IgG titres methylene blue-treated convalescent plasma)
Number of subjects: 376
Study 35150610 — intervention group
Group type: COMPARATOR
Intervention: Placebo (250 mL of sterile 0.9% saline solution)
Number of subjects: 376
Study 35150610 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Number of subjects: 376
Study 35150610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 376
Study 33539215 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Number of subjects: 4805
Study 33539215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4805
Study 32364879 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-out strategy for patient enrollment in surgical infection research
Number of subjects: 0
Study 32364879 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trial comparing surgery with non-operative intervention
Number of subjects: 0
Study 32364879 — intervention group
Group type: EXPERIMENTAL
Intervention: Open access journals
Number of subjects: 0
Study 32364879 — intervention group
Group type: EXPERIMENTAL
Intervention: Funding allocation
Number of subjects: 0
Study 34180500 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention for 10 weeks
Number of subjects: 61
Study 34180500 — intervention group
Group type: COMPARATOR
Intervention: Control group with routine exercises
Number of subjects: 61
Study 32945175 — intervention group
Group type: EXPERIMENTAL
Intervention: FDPP (faith-based diabetes prevention program)
Number of subjects: 221
Study 32945175 — intervention group
Group type: COMPARATOR
Intervention: SDPP (standard diabetes prevention program)
Number of subjects: 221
Study 34289408 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 488
Study 34289408 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 488
Study 32464566 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer simulation-based, interactive communication education (ComEd) program
Number of subjects: 131
Study 32464566 — intervention group
Group type: COMPARATOR
Intervention: Attention control (AC) program
Number of subjects: 131
Study 36266539 — intervention group
Group type: EXPERIMENTAL
Intervention: Baxdrostat 0.5 mg
Number of subjects: 54
Study 36266539 — intervention group
Group type: EXPERIMENTAL
Intervention: Baxdrostat 1.5 mg
Number of subjects: 54
Study 36266539 — intervention group
Group type: EXPERIMENTAL
Intervention: Baxdrostat 2.5 mg
Number of subjects: 54
Study 36266539 — intervention group
Group type: EXPERIMENTAL
Intervention: Baxdrostat 5.0 mg
Number of subjects: 54
Study 36266539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 32557911 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep group (2-hour nap opportunity)
Number of subjects: 0
Study 32557911 — intervention group
Group type: COMPARATOR
Intervention: Wake group (passively resting for 2 hours)
Number of subjects: 0
Study 32557911 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 35832302 — intervention group
Group type: EXPERIMENTAL
Intervention: Operating room nursing intervention and nanoceramic prosthesis
Number of subjects: 120
Study 35832302 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 120
Study 36429579 — intervention group
Group type: EXPERIMENTAL
Intervention: Moral public health messages
Number of subjects: 612
Study 36429579 — intervention group
Group type: EXPERIMENTAL
Intervention: Immoral public health messages
Number of subjects: 612
Study 36429579 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral public health messages
Number of subjects: 612
Study 36429579 — intervention group
Group type: EXPERIMENTAL
Intervention: Health benefits framing
Number of subjects: 612
Study 36429579 — intervention group
Group type: EXPERIMENTAL
Intervention: Health risks framing
Number of subjects: 612
Study 32201109 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine (TDB) patch 5 mcg applied at the end of surgery
Number of subjects: 200
Study 32201109 — intervention group
Group type: COMPARATOR
Intervention: Conventional analgesics (combination of paracetamol and tramadol)
Number of subjects: 200
Study 33749571 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine 1.5 mg/kg
Number of subjects: 24
Study 33749571 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet
Number of subjects: 24
Study 33749571 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine supplementation
Number of subjects: 24
Study 33749571 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet with thiamine
Number of subjects: 24
Study 33472582 — intervention group
Group type: EXPERIMENTAL
Intervention: SGB (Stellate Ganglion Block)
Number of subjects: 102
Study 33472582 — intervention group
Group type: COMPARATOR
Intervention: nSGB (no Stellate Ganglion Block)
Number of subjects: 102
Study 35323965 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 122
Study 34587700 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine milk-derived MFGM-enriched formula (MF)
Number of subjects: 212
Study 34587700 — intervention group
Group type: COMPARATOR
Intervention: Standard formula (SF)
Number of subjects: 212
Study 32645079 — intervention group
Group type: EXPERIMENTAL
Intervention: Roller pump (RP group)
Number of subjects: 80
Study 32645079 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugal pump (CFP group)
Number of subjects: 80
Study 32645079 — intervention group
Group type: COMPARATOR
Intervention: Both groups (RP and CFP)
Number of subjects: 80
Study 35143553 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient warning
Number of subjects: 8061
Study 35143553 — intervention group
Group type: COMPARATOR
Intervention: GDA
Number of subjects: 8061
Study 35143553 — intervention group
Group type: COMPARATOR
Intervention: Nutri-Score
Number of subjects: 8061
Study 35143553 — intervention group
Group type: COMPARATOR
Intervention: No label
Number of subjects: 8061
Study 34507061 — intervention group
Group type: EXPERIMENTAL
Intervention: Woebot‐SUDs (W‐SUDs) for 8 weeks
Number of subjects: 180
Study 34507061 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 180
Study 33669796 — intervention group
Group type: EXPERIMENTAL
Intervention: ME‐WE intervention consisting of seven 2‐h sessions in a group format based on Hayes and Ciarrochi’s psychoeducational model.
Number of subjects: 0
Study 33669796 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group.
Number of subjects: 0
Study 32149954 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingenol Mebutate Gel 0.05%
Number of subjects: 67
Study 32149954 — intervention group
Group type: COMPARATOR
Intervention: Podophyllin Solution 25%
Number of subjects: 67
Study 35114980 — intervention group
Group type: EXPERIMENTAL
Intervention: Ward-based intervention plus treatment as usual
Number of subjects: 34
Study 35114980 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual only
Number of subjects: 34
Study 33063201 — intervention group
Group type: EXPERIMENTAL
Intervention: Overuse Index (OI)
Number of subjects: 1994636
Study 33063201 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of primary care physicians (PCPs)
Number of subjects: 1994636
Study 33063201 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of low-income people
Number of subjects: 1994636
Study 32553436 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocktail therapy (20 mL of 0.75% ropivacaine, 5 mg of morphine, 0.3 mg of epinephrine, 2 mg of betamethasone, saline solution to a total of 42 mL)
Number of subjects: 128
Study 32553436 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocktail therapy
Number of subjects: 128
Study 32553436 — intervention group
Group type: COMPARATOR
Intervention: Control (20 mL of 0.75% ropivacaine and saline solution to a total of 42 mL)
Number of subjects: 128
Study 32553436 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 128
Study 35255913 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to specialized health facilities
Number of subjects: 152
Study 35255913 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to lower level facilities
Number of subjects: 152
Study 35255913 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider characteristics related to referrals
Number of subjects: 152
Study 35255913 — intervention group
Group type: EXPERIMENTAL
Intervention: Core-periphery correlation scores (CP) for provider networks
Number of subjects: 152
Study 35255913 — intervention group
Group type: EXPERIMENTAL
Intervention: Core-periphery correlation scores (CP) for facility networks
Number of subjects: 152
Study 34612707 — intervention group
Group type: EXPERIMENTAL
Intervention: RYGB-S (robotic approach)
Number of subjects: 495
Study 34612707 — intervention group
Group type: EXPERIMENTAL
Intervention: RYGB-Xi (robotic approach)
Number of subjects: 495
Study 34612707 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic RYGB
Number of subjects: 495
Study 36063807 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional formula
Number of subjects: 98
Study 36063807 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional formula (good consumers, intake ≥50% of recommended dose)
Number of subjects: 98
Study 36063807 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional formula (poor consumers, intake <50% of recommended dose)
Number of subjects: 98
Study 36063807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 34909955 — intervention group
Group type: EXPERIMENTAL
Intervention: Group hope therapy (8 sessions of 90 minutes each using Snyder's method)
Number of subjects: 45
Study 34909955 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 45
Study 34909955 — intervention group
Group type: EXPERIMENTAL
Intervention: Group hope therapy
Number of subjects: 45
Study 35651824 — intervention group
Group type: EXPERIMENTAL
Intervention: BTP+TAU
Number of subjects: 34
Study 35651824 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 34
Study 34628735 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held moxibustion
Number of subjects: 90
Study 34628735 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion shelf
Number of subjects: 90
Study 34628735 — intervention group
Group type: COMPARATOR
Intervention: Imitation moxibustion apparatus
Number of subjects: 90
Study 34320552 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Sleep Disturbance and Fatigue (CBT‐SF)
Number of subjects: 30
Study 34320552 — intervention group
Group type: COMPARATOR
Intervention: Attentionally equivalent health education control
Number of subjects: 30
Study 33273579 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced education level
Number of subjects: 11509
Study 33273579 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate education level
Number of subjects: 11509
Study 33273579 — intervention group
Group type: EXPERIMENTAL
Intervention: Education (Mendelian randomization analysis)
Number of subjects: 11509
Study 33273579 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education level
Number of subjects: 11509
Study 32679601 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-bite technique
Number of subjects: 48
Study 32679601 — intervention group
Group type: COMPARATOR
Intervention: Double-bite technique
Number of subjects: 48